News & Events

• June 29, 2022
  

  C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research

  C-Path and Replica Analytics, an Aetion company, announced today a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases.

• June 7, 2022
  

  C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease

  C-Path and MitoAction today announced a joint collaboration to incorporate patient data for rare mitochondrial disorders into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).

• May 31, 2022
  

  FSHD Society and Critical Path Institute Collaborate to Collect Clinical Trial Data

  The FSHD Society, a research-focused patient advocacy nonprofit dedicated to bringing treatments to patients affected by facioscapulohumeral muscular dystrophy (FSHD), has partnered with Critical Path Institute (C-Path) to facilitate the integration of clinical trial data from the control arm of various FSHD-related clinical studies into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP ^®). These data will come from several companies that have sponsored clinical trials in FSHD.

• April 28, 2022
  

  C-Path to Lead Novel Pre-Consortium Framework for Optimizing the Rare and Orphan Medical Product Lifecycle

  C-Path, in collaboration with one of the industry’s prominent rare and orphan (R&O) thought leaders, Maryna Kolochavina, Pharm.D., Ph.D., today announced the launch of unique pre-consortium collaboration, bringing together industry leaders and stakeholders to accelerate and standardize key constructs for the efficient development, approval and access to R&O medical products.

• November 9, 2021
  

  C-Path and Cure Mito Announce Data Sharing Agreement to Support Treatment Development For Leigh Syndrome and Mitochondrial Disease

  Critical Path Institute (C-Path) and Cure Mito Foundation (Cure Mito) today announced a joint collaboration to significantly promote data sharing and accelerate Leigh syndrome and other rare mitochondrial disease data incorporation into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).